Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Non-Current Debt (2016 - 2020)

Amicus Therapeutics filings provide 10 years of Non-Current Debt readings, the most recent being $147.8 million for Q2 2020.

  • On a quarterly basis, Non-Current Debt rose 0.57% to $147.8 million in Q2 2020 year-over-year; TTM through Jun 2020 was $147.8 million, a 0.57% increase, with the full-year FY2019 number at $147.4 million, changed 0.44% from a year prior.
  • Non-Current Debt hit $147.8 million in Q2 2020 for Amicus Therapeutics, roughly flat from $147.6 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $147.8 million in Q2 2020 to a low of $21.9 million in Q2 2016.
  • Median Non-Current Debt over the past 4 years was $146.8 million (2019), compared with a mean of $114.5 million.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 318.21% in 2016 and later increased 0.37% in 2019.
  • Amicus Therapeutics' Non-Current Debt stood at $22.0 million in 2016, then soared by 567.67% to $146.7 million in 2018, then increased by 0.44% to $147.4 million in 2019, then rose by 0.31% to $147.8 million in 2020.
  • The last three reported values for Non-Current Debt were $147.8 million (Q2 2020), $147.6 million (Q1 2020), and $147.4 million (Q4 2019) per Business Quant data.